Lithuanian biotech Atrandi Biosciences (former Droplet Genomics) raised €4,5M

Lithuanian biotechnology startup Atrandi Biosciences (former Droplet Genomics) raised €4,5M from lead investor German VC Vsquared Ventures. Investors from the previous round, Lithuanian fund Practica Capital, and a new investor Estonian fund Metaplanet also participated in the round.

Atrandi Biosciences provides droplet microfluidics technology which enables compartmentalizing molecular biology reactions into millions of pico-liter droplets. Thus, it is possible to study biological samples at the resolution of single cells and single molecules. Also, the company has developed a Semi-Permeable Capsule technology that enables multi-step workflows in a droplet format for high-throughput analysis of biological samples. Atrandi Biosciences’ capsule technology could be applied in cell therapy research, genome sequencing, AI-driven drug discovery, or personalized medicine. In particular, it could support accelerating research in individualized treatment for cancer patients.

The startup changed its name to Atrandi Biosciences due to its expansion strategy to a global market. Atrandi Biosciences hired employees for its office in the US, and it plans to continue the global commercialization of droplet microfluidic and single-cell analysis technologies.

Atrandi Biosciences (former Droplet Genomics) was established in Lithuania in 2018 by Juozas Nainys, Karolis Leonavičius, Dalius Kučiauskas, and Linas Mažutis. In 2021 it received €1M from the Lithuanian fund Practica Capital.